🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/01/2005 12,54 12,54 12,06 12,24 -2,39% 3,83% 47.367
10/01/2005 12,60 12,96 12,42 12,54 -0,95% 4,29% 30.067
07/01/2005 12,72 12,84 12,60 12,66 -1,86% 1,89% 9.250
06/01/2005 12,72 13,08 12,66 12,90 +1,42% 3,30% 24.467
05/01/2005 13,20 13,20 12,72 12,72 -1,85% 3,64% 23.983
04/01/2005 13,80 13,80 12,90 12,96 -4,00% 6,52% 50.400
03/01/2005 14,34 14,40 13,50 13,50 -4,26% 6,28% 29.983
31/12/2004 13,74 14,64 13,50 14,10 +3,07% 8,30% 73.917
30/12/2004 13,50 13,86 13,26 13,68 +0,44% 4,44% 45.767
29/12/2004 13,62 13,92 13,38 13,62 +0,44% 3,96% 42.333
28/12/2004 12,90 14,10 12,84 13,56 +4,63% 9,77% 119.933
27/12/2004 12,96 13,26 12,78 12,96 +0,47% 3,70% 31.400
23/12/2004 12,84 13,02 12,84 12,90 +0,94% 1,40% 20.117
22/12/2004 13,44 13,56 12,72 12,78 -1,39% 6,25% 38.500
21/12/2004 13,98 14,10 12,90 12,96 -4,00% 8,58% 73.567
20/12/2004 13,62 14,04 13,26 13,50 -2,17% 5,73% 61.867
17/12/2004 12,48 14,10 12,48 13,80 +10,05% 12,98% 159.183
16/12/2004 12,60 12,78 12,48 12,54 -1,42% 2,38% 31.733
15/12/2004 12,72 12,78 12,48 12,72 -0,93% 2,36% 21.433
14/12/2004 12,54 12,84 12,48 12,84 +2,88% 2,87% 28.017
13/12/2004 13,14 13,14 12,36 12,48 +0,48% 5,94% 31.417
10/12/2004 12,36 13,02 12,36 12,42 -1,43% 5,34% 27.750
09/12/2004 13,14 13,14 12,36 12,60 +0,00% 5,94% 33.483
08/12/2004 13,38 13,44 12,48 12,60 -4,98% 7,17% 30.967
07/12/2004 13,44 13,68 13,02 13,26 +0,45% 4,91% 39.167
06/12/2004 13,44 13,56 13,02 13,20 +0,46% 4,02% 21.517
03/12/2004 13,62 13,62 13,02 13,14 -1,79% 4,41% 16.817
02/12/2004 13,20 13,50 12,90 13,38 +3,24% 4,55% 25.617
01/12/2004 13,32 13,38 12,90 12,96 -0,46% 3,60% 14.267
30/11/2004 13,44 13,80 13,02 13,02 -1,36% 5,80% 16.750